Drug Trial Radar · NCT07710612
A Phase 2 Study of ABSK043 Combined With Osimertinib
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
Conditions
- Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Interventions
ABSK043 in combination with OsimertinibDrug
Three potential dose levels of ABSK043 are prespecified, and Osimertinib will be administered orally at a fixed dose of 80 mg QD in escalation cohort. Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- - Incidence of dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Adverse events(AEs)Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.
- Serious adverse events (SAEs)Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.
- Adverse events of special interest (AESIs)Time frame: From the time the patient signs the informed consent form throughout the study and up to 30 days (± 7 days) after the last dose of ABSK043 or Osimertinib, up to 30 months.
- Progression-free survival at 12 monthTime frame: From the time patients receive the first dose of study drug to 12 months,assessed up to 5 years.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.